Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura (Q33365619)

26 July 2017

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1 reference

Hans C Hasselbalch

14

0 references

author name string

Peter Braendstrup

1

1 reference

26 July 2017

Ole W Bjerrum

2

1 reference

26 July 2017

Ove J Nielsen

3

1 reference

26 July 2017

Bjarne A Jensen

4

1 reference

26 July 2017

Nielsaage T Clausen

5

1 reference

26 July 2017

Per Boye Hansen

6

1 reference

26 July 2017

Ivan Andersen

7

1 reference

26 July 2017

Kai Schmidt

8

1 reference

26 July 2017

Torben M Andersen

9

1 reference

26 July 2017

Niels A Peterslund

10

1 reference

26 July 2017

Henrik S Birgens

11

1 reference

26 July 2017

Torben Plesner

12

1 reference

26 July 2017

Bjarne B Pedersen

13

1 reference

26 July 2017

1 April 2005

1 reference

American Journal of Hematology

26 July 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 July 2017

78

1 reference

26 July 2017

4

1 reference

26 July 2017

275-280

1 reference

Immune thrombocytopenic purpura

26 July 2017

1 reference

Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses

21 January 2018

1 reference

Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults

21 January 2018

1 reference

Morbidity and mortality in adults with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.

21 January 2018

1 reference

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome

21 January 2018

1 reference

The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

21 January 2018

1 reference

Late and long-lasting response in an adult chronic idiopathic thrombocytopenic purpura after extended course of rituximab

21 January 2018

1 reference

Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).

21 January 2018

1 reference

Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment

21 January 2018

1 reference

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

21 January 2018

1 reference

Rituximab in the treatment of acquired factor VIII inhibitors

21 January 2018

1 reference

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

21 January 2018

1 reference

Rituximab for the treatment of type II mixed cryoglobulinemia

21 January 2018

1 reference

Rituximab for idiopathic membranous nephropathy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.20276

1 reference

26 July 2017

1 reference